Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin.

about

Progress in protein structure and function studies in China during 2010-2011.A novel antibody-drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity.

P2860

Q30422963-86B25101-1F52-4942-B3DE-263310969751 Q38850042-9974AD93-4945-4DB1-99C5-BACD241D0D35

P2860

Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin.

Item

http://www.wikidata.org/entity/Q39574303

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Antitumor effects of an engine ...... 0 scFv fragment and lidamycin.

@en

Antitumor effects of an engine ...... 0 scFv fragment and lidamycin.

@nl

type

Item

label

Antitumor effects of an engine ...... 0 scFv fragment and lidamycin.

@en

Antitumor effects of an engine ...... 0 scFv fragment and lidamycin.

@nl

prefLabel

Antitumor effects of an engine ...... 0 scFv fragment and lidamycin.

@en

Antitumor effects of an engine ...... 0 scFv fragment and lidamycin.

@nl

P1476

Antitumor effects of an engine ...... 0 scFv fragment and lidamycin.

@en

P2093

Dongsheng Xiong

http://www.w3.org/2001/XMLSchema#string

Hong Fang

http://www.w3.org/2001/XMLSchema#string

Qingfang Miao

http://www.w3.org/2001/XMLSchema#string

Shenghua Zhang

http://www.w3.org/2001/XMLSchema#string

Xin Cheng

http://www.w3.org/2001/XMLSchema#string

Yongsu Zhen

http://www.w3.org/2001/XMLSchema#string

P2860

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.

Rituximab use in pediatric autoimmune diseases: four case reports.

Lidamycin shows highly potent cytotoxic to myeloma cells and inhibits tumor growth in mice

Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy.

Rituximab: mechanism of action and resistance.

Antitumor efficacy of lidamycin on hepatoma and active moiety of its molecule

Antibody-targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin lymphoma.

Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions.

Enediyne anticancer antibiotic lidamycin: chemistry, biology and pharmacology.

Use of rituximab in diffuse large B-cell lymphoma in the salvage setting.

P2888

s11427-011-4143-4

P304

255-262

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11427-011-4143-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50421083

http://www.w3.org/2001/XMLSchema#string

P698

21416325

http://www.w3.org/2001/XMLSchema#string

Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin.

about

P2860

P2860

Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698